Reproductive technology

Bringing advanced fertility care within reach

EVEA™ IntraVaginal Culture (IVC) lets healthcare networks deliver assisted reproduction — without the cleanroom, without a dedicated embryology laboratory, without the infrastructure barrier.

Request a briefing →
In underserved markets, the embryology lab is the binding constraint
Every conventional IVF cycle consumes scarce embryology capacity — lab space, incubator capacity and specialist time. EVEA™ is designed to remove that infrastructure constraint.
1 in 6
people affected by infertility worldwide — a WHO-recognised disease.
$1M+
illustrative capital benchmark to build a conventional embryology cleanroom — varies by country, facility and scope.
~59%
fewer embryology-lab hours per cycle — Eve operational model, not clinical-trial data.
35+ yrs
of published intravaginal-culture clinical history.
Sources: WHO; market benchmarks (BDA Partners, SART). Operational figure reflects Eve cycle modelling.

Expanding the capacity for fertility care.

In underserved markets, fertility care is constrained less by demand than by infrastructure — the embryology laboratory every conventional IVF cycle depends on. Eve exists to lift that constraint. By relocating the multi-day culture phase in-vivo, EVEA™ lets hospitals use their existing operating theatre, andrology lab and embryology staff — while eliminating the cleanroom, incubator bank and HEPA filtration that make conventional IVF impractical in secondary cities. Our focus is Asia-Pacific, and in particular the secondary cities and underserved regions conventional infrastructure has never reached.

What we are

A medical-device company

Eve develops EVEA™, an intravaginal culture device, and the activation platform around it — built to medical-device regulatory and manufacturing standards.

How we earn

A recurring per-cycle model

Eve earns a recurring per-cycle platform fee. We grow as our partners run more cycles — our incentives are aligned with theirs.

How we scale

Replication, not ownership

One activation model, deployed site by site across Asia-Pacific — recurring on participation rather than tied to infrastructure we own.

Built for Asia-Pacific — to bring advanced fertility care to the secondary cities and underserved regions that conventional embryology infrastructure does not reach.

EVEA™ decentralizes the culture phase, so a hospital may offer selected assisted-reproduction services without building the full embryology infrastructure a major urban IVF centre requires.

Operators who have built fertility markets across APAC.

Eve is led by a team combining deep MedTech commercial experience with clinical and regulatory expertise — Founder & CEO Yve Lyppens and Co-Founder & Director of Medical Affairs Col. Dr. Othman Sukhilmi.

Meet the team →

Based in Hong Kong, focused on APAC.

Eve Fertility Ltd. is incorporated in Hong Kong SAR, with an active deployment pipeline across Asia-Pacific — the secondary-city hospital systems where fertility infrastructure does not yet exist.

Work with us

Evaluate EVEA™ for your institution.

For hospital systems, fertility operators, investors, regulators and partners across Asia-Pacific.

Request a briefing → Explore EVEA™